Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine versus beta-blocker for premature ventricular complexes
IRCT20251118068036N1Phase 3Recruiting
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ranolazine, bisoprolol and metoprolol in Premature ventricular complexes (PVC) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Reduction in premature ventricular complexes and Improvement in clinical symptoms. Started Jan 2026; status: recruiting.
02
Drugs
ranolazinebisoprololmetoprolol
03
Conditions
Premature ventricular complexes (PVC)
Beyond the preview
Go deeper on IRCT20251118068036N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251118068036N1.